BRAFV600E Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis
Open Access
- 3 March 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (3), e90607
- https://doi.org/10.1371/journal.pone.0090607
Abstract
Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. The B-type Raf proto-oncogene (BRAF) plays an important role in the mitogen-activated protein kinase (MAPK) signaling cascade during CRC. The presence of BRAFV600E mutation can determine the response of a tumor to chemotherapy. However, the association between the BRAFV600E mutation and the clinicopathological features of CRC remains controversial. We performed a systematic review and meta-analysis to estimate the effect of BRAFV600E mutation on the clinicopathological characteristics of CRC. We identified studies that examined the effect of BRAFV600E mutation on CRC within the PubMed, ISI Science Citation Index, and Embase databases. The effect of BRAFV600E on outcome parameters was estimated by odds ratios (ORs) with 95% confidence intervals (CIs) for each study using a fixed effects or random effects model. 25 studies with a total of 11,955 CRC patients met inclusion criteria. The rate of BRAFV600 was 10.8% (1288/11955). The BRAFV600E mutation in CRC was associated with advanced TNM stage, poor differentiation, mucinous histology, microsatellite instability (MSI), CpG island methylator phenotype (CIMP). This mutation was also associated with female gender, older age, proximal colon, and mutL homolog 1 (MLH1) methylation. This meta-analysis demonstrated that BRAFV600E mutation was significantly correlated with adverse pathological features of CRC and distinct clinical characteristics. These data suggest that BRAFV600E mutation could be used to supplement standard clinical and pathological staging for the better management of individual CRC patients, and could be considered as a poor prognostic marker for CRC.Keywords
This publication has 40 references indexed in Scilit:
- Predictive and Prognostic Roles ofBRAFMutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803Clinical Cancer Research, 2012
- Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal CancerJournal of Clinical Oncology, 2011
- KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancerOncology Reports, 2011
- The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patientsAnnals Of Oncology, 2010
- Is BRAF Mutation Associated with Interval Colorectal Cancers?Digestive Diseases and Sciences, 2010
- Ethnicity and Risk for Colorectal Cancers Showing Somatic BRAF V600E Mutation or CpG Island Methylator PhenotypeCancer Epidemiology, Biomarkers & Prevention, 2008
- Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon CancerClinical Cancer Research, 2008
- Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for Hereditary Nonpolyposis Colorectal CancerCancer Detection Prevention, 2007
- Association of Smoking, CpG Island Methylator Phenotype, and V600E BRAF Mutations in Colon CancerJNCI Journal of the National Cancer Institute, 2006
- CpG island methylator phenotype in cancerNature Reviews Cancer, 2004